Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00968331
Recruitment Status : Terminated (The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and Supporter (Celgene))
First Posted : August 31, 2009
Last Update Posted : August 27, 2012
Information provided by (Responsible Party):
Pier Luigi Zinzani, University of Bologna

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : December 2009
  Actual Study Completion Date : December 2011